TCBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Texas Capital Bancshares Inc (TCBI) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive revenue and EPS trends, and hedge fund interest. While analyst ratings are mixed, the stock's technical indicators and recent financial performance support a favorable long-term outlook.
The technical indicators for TCBI are bullish. The MACD histogram is positive at 0.36, indicating upward momentum. The RSI is neutral at 59.454, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 103.127, with resistance at 105.983 and support at 100.272.
Strong Q1 2026 financial performance with revenue up 15.57% YoY and EPS up 69.57% YoY.
Hedge funds are significantly increasing their positions in the stock, with a 640.85% increase in buying activity.
Recent dividend declaration reflects a commitment to shareholder returns.
Positive momentum in the company's mortgage finance, wealth management, and investment banking businesses.
Mixed analyst ratings with some firms maintaining Neutral or Underweight ratings.
Concerns over meaningful loan and deposit growth as highlighted by analysts.
No recent congress trading data or significant insider activity to provide additional confidence.
In Q1 2026, Texas Capital Bancshares reported a 15.57% YoY increase in revenue to $312.6 million, a 62.58% YoY increase in net income to $69.5 million, and a 69.57% YoY increase in EPS to $1.56. The company beat EPS expectations by $0.17 and demonstrated strong growth trends.
Analyst ratings are mixed. Piper Sandler raised the price target to $100 but kept a Neutral rating, citing strong fee income and net interest margin growth. BofA lowered the price target to $107 but maintained a Buy rating. JPMorgan reduced the price target to $100 with an Underweight rating, citing macroeconomic concerns. Keefe Bruyette and TD Cowen raised their price targets to $110, with Keefe maintaining an Outperform rating.
